Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dodekin - Philogen

Next Previous
Drug Profile

Dodekin - Philogen

Alternative Names: IL12-L19L19; L19-IL12

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Philogen
  • Class Antibodies; Antineoplastics; Immunotherapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Diffuse large B cell lymphoma; Solid tumours

Most Recent Events

  • 26 Feb 2024 Efficacy, adverse events and pharmacokinetics data from the phase I DODEKA trial in solid tumours presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)
  • 20 Oct 2023 Efficacy and adverse events data from the phase I DODEKA trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 28 Aug 2023 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(In the elderly, Late-stage disease, Mid-stage disease, Second-line therapy or greater, In adults) in Italy (Parenteral, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top